Cytokinetics (FRA:KK3A) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KK3A Cytokinetics Inc FRA:KK3A
51 GF Score
Price €69.80
GF Value €219.44
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Cytokinetics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cytokinetics Valuation Rank Related Terms

FRA:KK3A
51GF Score
Cytokinetics Inc FRA:KK3A
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cytokinetics (FRA:KK3A) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of €69.80 is trading 68.2% below its estimated GF Value™ of €219.44. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for FRA:KK3A:

  • Valuation Rank:
  • GF Value™: €219.44 vs. price of €69.80 (68.2% below fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the FRA:KK3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytokinetics Business Description

Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
51GF Score

Get the complete analysis for FRA:KK3A

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.80
Price
€219.44
GF Value